Jean F. Holloway Sells 23,356 Shares of Artivion, Inc. (NYSE:AORT) Stock

Key Points

• Jean F. Holloway, SVP of Artivion, sold 23,356 shares of the company's stock, valued at approximately $1,004,541, representing an 11.95% decrease in their position.
• Artivion reported a Q2 EPS of $0.24, exceeding expectations and showing a 15.3% increase in revenue compared to the same quarter last year.
• Institutional investors hold 86.37% of Artivion's stock, with notable increases in holdings from firms like JPMorgan Chase & Co. and LPL Financial LLC.

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean F. Holloway sold 23,356 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the transaction, the senior vice president owned 172,129 shares of the company's stock, valued at $7,403,268.29. This trade represents a 11.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Artivion Trading Down 0.4%

AORT stock traded down $0.17 during mid-day trading on Friday, reaching $42.78. 502,276 shares of the stock traded hands, compared to its average volume of 535,231. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. Artivion, Inc. has a one year low of $21.97 and a one year high of $43.97. The stock has a market capitalization of $2.02 billion, a PE ratio of -101.86 and a beta of 1.64. The business has a 50-day moving average price of $32.22 and a two-hundred day moving average price of $28.43.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. The business had revenue of $112.97 million for the quarter, compared to analysts' expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company's revenue for the quarter was up 15.3% compared to the same quarter last year. Equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. JMP Securities raised their price objective on shares of Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research note on Friday, August 8th. Oppenheimer reaffirmed an "outperform" rating on shares of Artivion in a report on Friday, August 8th. Wall Street Zen downgraded shares of Artivion from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $45.00 price target (up previously from $32.00) on shares of Artivion in a report on Friday, August 8th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $39.80.

Institutional Trading of Artivion

A number of hedge funds have recently added to or reduced their stakes in AORT. Legacy Advisors LLC purchased a new stake in shares of Artivion during the first quarter valued at about $28,000. MCF Advisors LLC lifted its position in shares of Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after buying an additional 614 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after buying an additional 538 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Artivion during the fourth quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Artivion by 447.6% during the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company's stock valued at $168,000 after buying an additional 4,422 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.